EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC 4.0

First versus second-generation molecular profiling tests: How both can guide decision-making in early-stage hormone-receptor positive breast cancers?

Flora Nguyen Van Long, Brigitte Poirier, Christine Desbiens, Marjorie Perron, Claudie Paquet, Cathie Ouellet, Caroline Diorio, Julie Lemieux, Hermann Nabi

Cancer Treatment Reviews · 2025-04 · 135 · 102909

DOI: 10.1016/j.ctrv.2025.102909 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Cancer Treatment Reviews, 2025-04. Verfasst von Flora Nguyen Van Long und 8 weiteren Autor:innen. Beteiligte Einrichtung: Oncology Axis, Centre Hospitalier Universitaire de Québec Research Center - Université Laval (CRCHUQc-UL), Quebec city, QC G1V 4G2, Canada. Hauptthemen laut MEDLINE: Breast Neoplasms, Gene Expression Profiling. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 65 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Quebec Health Research Fund, Génome Québec.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Breast NeoplasmsGene Expression ProfilingHumansFemaleReceptors, EstrogenErb-b2 Receptor Tyrosine KinasesReceptors, ProgesteroneClinical Decision-MakingBiomarkers, TumorPrognosisChemotherapy, AdjuvantNeoplasm Staging

Stichwörter der Autor:innen

Clinical-decision support toolsHormone receptor-positive breast cancersMolecular testsOncotype DXProsigna

Substanzen

Receptors, EstrogenErb-b2 Receptor Tyrosine KinasesReceptors, ProgesteroneBiomarkers, TumorERBB2 protein, human

Autor:innen und Institutionen

  • Oncology Axis, Centre Hospitalier Universitaire de Québec Research Center - Université Laval (CRCHUQc-UL), Quebec city, QC G1V 4G2, Canada.
  • Oncology Axis, Centre Hospitalier Universitaire de Québec Research Center - Université Laval (CRCHUQc-UL), Quebec city, QC G1V 4G2, Canada; Centre des maladies du sein, CHU de Québec-Université Laval, Quebec city, QC G1…
  • Pathology department, CHU de Québec-Université Laval, Quebec city, QC G1V 4G2, Canada.
  • Oncology Axis, Centre Hospitalier Universitaire de Québec Research Center - Université Laval (CRCHUQc-UL), Quebec city, QC G1V 4G2, Canada; Department of Social and Preventive Medicine, Faculty of Medicine, Université L…

Förderung

  • Quebec Health Research Fund
  • Génome Québec

Zitieren

APA

Nguyen Van Long, F., Poirier, B., Desbiens, C., Perron, M., Paquet, C., Ouellet, C., Diorio, C., Lemieux, J., & Nabi, H. (2025). First versus second-generation molecular profiling tests: How both can guide decision-making in early-stage hormone-receptor positive breast cancers?. Cancer Treatment Reviews, 135, 102909. https://doi.org/10.1016/j.ctrv.2025.102909

Vancouver

Nguyen Van Long F, Poirier B, Desbiens C, Perron M, Paquet C, Ouellet C, et al. First versus second-generation molecular profiling tests: How both can guide decision-making in early-stage hormone-receptor positive breast cancers?. Cancer Treatment Reviews. 2025;135:102909. doi:10.1016/j.ctrv.2025.102909

BibTeX
@article{NguyenVanLong2025,
  author = {Nguyen Van Long, Flora and Poirier, Brigitte and Desbiens, Christine and Perron, Marjorie and Paquet, Claudie and Ouellet, Cathie and Diorio, Caroline and Lemieux, Julie and Nabi, Hermann},
  title = {First versus second-generation molecular profiling tests: How both can guide decision-making in early-stage hormone-receptor positive breast cancers?},
  journal = {Cancer Treatment Reviews},
  year = {2025},
  volume = {135},
  pages = {102909},
  doi = {10.1016/j.ctrv.2025.102909}
}
Kostenlos starten →